This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022;12(1):7-11. doi:10.1016/j.kisu.2021.11.003Open DOISearch in Google Scholar
Sundström J, Bodegard J, Bollmann A, et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study. The Lancet Regional Health - Europe. 2022;20:100438. doi:10.1016/J.LANEPE.2022.100438Open DOISearch in Google Scholar
Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation. 2021;143(11):1157-1172. doi:10.1161/CIRCULATIONAHA.120.050686Open DOISearch in Google Scholar
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C yuan. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-1305. doi:10.1056/NEJMoa041031Open DOISearch in Google Scholar
Vallianou NG, Mitesh S, Gkogkou A, Geladari E. Chronic Kidney Disease and Cardiovascular Disease: Is there Any Relationship? Curr Cardiol Rev. 2019;15(1):55-63. doi:10.2174/1573403X14666180711124825Open DOISearch in Google Scholar
Buckley LF, Schmidt IM, Verma A, et al. Associations Between Kidney Histopathologic Lesions and Incident Cardiovascular Disease in Adults With Chronic Kidney Disease. JAMA Cardiol. 2023;8(4):357-365. doi:10.1001/jamacardio.2023.0056Open DOISearch in Google Scholar
Ocak G, Rookmaaker MB, Algra A, et al. Chronic kidney disease and bleeding risk in patients at high cardiovascular risk: a cohort study. Journal of Thrombosis and Haemostasis. 2018;16(1):65-73. doi:10.1111/jth.13904Open DOISearch in Google Scholar
Sood MM, Bota SE, Mcarthur E, et al. The Three-Year Incidence of Major Hemorrhage among Older Adults Initiating Chronic Dialysis.; 2014. http://www.cjkhd.org/content/1/1/21Search in Google Scholar
Kuo CC, Kuo HW, Lee IM, Lee CT, Yang CY. The Risk of Upper Gastrointestinal Bleeding in Patients Treated with Hemodialysis: A Population-Based Cohort Study.; 2013. http://www.biomedcentral.com/1471-2369/14/15Search in Google Scholar
Liao JN, Chao TF, Liu CJ, et al. Incidence and risk factors for new-onset atrial fibrillation among patients with end-stage renal disease undergoing renal replacement therapy. Kidney Int. 2015;87(6):1209-1215. doi:10.1038/ki.2014.393Open DOISearch in Google Scholar
Official JOurnal Of the InternatiOnal SOciety Of NephrOlOgy KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. www.publicationethics.orgSearch in Google Scholar
Christiansen CF, Schmidt M, Lamberg AL, et al. Kidney disease and risk of venous thromboembolism: a nationwide population-based case-control study. J Thromb Haemost. 2014;12(9):1449-1454. doi:10.1111/jth.12652Open DOISearch in Google Scholar
Wanner C, Herzog CA, Turakhia MP, Conference Steering Committee. Chronic kidney disease and arrhythmias: highlights from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2018;94(2):231-234. doi:10.1016/j.kint.2018.05.005Open DOISearch in Google Scholar
Aursulesei V, Costache II. Anticoagulation in chronic kidney disease: from guidelines to clinical practice. Clin Cardiol. 2019;42(8):774-782. doi:10.1002/clc.23196Open DOISearch in Google Scholar
Pawar P, Kota A, Sen I, et al. Chronic kidney disease and anticoagulation - Quick overview and practical guide. Indian Journal of Vascular and Endovascular Surgery. 2022;9(1):40. doi:10.4103/ijves.ijves_90_21Open DOISearch in Google Scholar
Derebail VK, Rheault MN, Kerlin BA. Role of direct oral anticoagulants in patients with kidney disease. Kidney Int. 2020;97(4):664-675. doi:10.1016/j.kint.2019.11.027Open DOISearch in Google Scholar
Sy J, Hsiung JT, Edgett D, Kalantar-Zadeh K, Streja E, Lau WL. Cardiovascular and Bleeding Outcomes with Anticoagulants across Kidney Disease Stages: Analysis of a National US Cohort. Am J Nephrol. 2021;52(3):199-208. doi:10.1159/000514753Open DOISearch in Google Scholar
Burlacu A, Genovesi S, Ortiz A, et al. Pros and cons of antithrombotic therapy in end-stage kidney disease: a 2019 update. Nephrol Dial Transplant. 2019;34(6):923-933. doi:10.1093/ndt/gfz040Open DOISearch in Google Scholar
Parker K, Thachil J. The use of direct oral anticoagulants in chronic kidney disease. Br J Haematol. 2018;183(2):170-184. doi:10.1111/bjh.15564Open DOISearch in Google Scholar
Rovin BH, Adler SG, Barratt J, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4):S1-S276. doi:10.1016/j.kint.2021.05.021Open DOISearch in Google Scholar
Official JOurnal Of the InternatiOnal SOciety Of NephrOlOgy KDIGO Clinical Practice Guideline for Glomerulonephritis.; 2012. http://www.kidney-international.orgSearch in Google Scholar
Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-1304. doi:10.1136/annrheumdis-2019-215213Open DOISearch in Google Scholar
Dufrost V, Risse J, Zuily S, Wahl D. Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature. Curr Rheumatol Rep. 2016;18(12):74. doi:10.1007/s11926-016-0623-7Open DOISearch in Google Scholar
Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, et al. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial. Ann Intern Med. 2019;171(10):685-694. doi:10.7326/M19-0291Open DOISearch in Google Scholar
Kronbichler A, Leierer J, Shin J Il, et al. Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2019;71(11):1888-1893. doi:10.1002/art.41017Open DOISearch in Google Scholar
Carli G, Farsi A, Chiarini F, Lippolis D, Cortellini G. Hypersensitivity reactions to non-vitamin K oral anticoagulants - a review of literature and diagnostic work-up proposal. Eur Ann Allergy Clin Immunol. 2019;51(1):7-14. doi:10.23822/EurAnnACI.1764-1489.80Open DOISearch in Google Scholar
Huang MJ, Wei RB, Wang Y, et al. Blood coagulation system in patients with chronic kidney disease: A prospective observational study. BMJ Open. 2017;7(5). doi:10.1136/bmjopen-2016-014294Open DOISearch in Google Scholar
Baaten CCFMJ, Schröer JR, Floege J, et al. Platelet Abnormalities in CKD and Their Implications for Antiplatelet Therapy. Clinical Journal of the American Society of Nephrology. 2022;17(1):155-170. doi:10.2215/CJN.04100321Open DOISearch in Google Scholar
Visseren FLJ, MacH F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. doi:10.1093/eurheartj/ehab484Open DOISearch in Google Scholar
Taliercio JJ, Nakhoul G, Mehdi A, et al. Aspirin for Primary and Secondary Prevention of Mortality, Cardiovascular Disease, and Kidney Failure in the Chronic Renal Insufficiency Cohort (CRIC) Study. Kidney Med. 2022;4(11). doi:10.1016/j.xkme.2022.100547Open DOISearch in Google Scholar
Wolfe R, Wetmore JB, Woods RL, et al. Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease. Kidney Int. 2021;99(2):466-474. doi:10.1016/j.kint.2020.08.011Open DOISearch in Google Scholar
Jardine MJ, Ninomiya T, Perkovic V, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: A post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol. 2010;56(12):956-965. doi:10.1016/j.jacc.2010.02.068Open DOISearch in Google Scholar
Goicoechea M, de Vinuesa SG, Quiroga B, et al. Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study). Cardiovasc Drugs Ther. 2018;32(3):255-263. doi:10.1007/s10557-018-6802-1Open DOISearch in Google Scholar
Floyd CN, Passacquale G, Ferro A. Comparative Pharmacokinetics and Pharmacodynamics of Platelet Adenosine Diphosphate Receptor Antagonists and Their Clinical Implications.Search in Google Scholar
Frere C, Cuisset T, Quilici J, et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost. 2007;98(4):838-843.Search in Google Scholar
Guo LZ, Kim MH, Shim CH, Choi SY, Serebruany VL. Impact of renal impairment on platelet reactivity and clinical outcomes during chronic dual antiplatelet therapy following coronary stenting. Eur Heart J Cardiovasc Pharmacother. 2016;2(3):145-151. doi:10.1093/ehjcvp/pvv052Open DOISearch in Google Scholar
Baber U, Mehran R, Kirtane AJ, et al. Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry. Circ Cardiovasc Interv. 2015;8(6):e001683. doi:10.1161/CIRCINTERVENTIONS.115.001683Open DOISearch in Google Scholar
Geara AS, Ayoub I, Abi Rached J, Siddique MN, Ghimire P, El-Sayegh S. Does hemodialysis affect clopidogrel resistance as measured by VerifyNow P2Y12 test? Am J Cardiol.2011; 107(7):1103-1104. doi:10.1016/j.amjcard.2011.01.003Open DOISearch in Google Scholar
Melloni C, Cornel JH, Hafley G, et al. Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial. Eur Heart J Acute Cardiovasc Care. 2016;5(6):443-454. doi:10.1177/2048872615598631Open DOISearch in Google Scholar
Keltai M, Tonelli M, Mann JFE, et al. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Cardiovasc Prev Rehabil. 2007;14 (2):312-318.doi:10.1097/01.hjr.0000220582.19516.a6Open DOISearch in Google Scholar
Best PJM, Steinhubl SR, Berger PB, et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J. 2008;155(4):687-693. doi:10.1016/j.ahj.2007.10.046Open DOISearch in Google Scholar
Trimarchi H, Young P, Forrester M, Schropp J, Pereyra H, Freixas E. Clopidogrel diminishes hemodialysis access graft thrombosis. J Vasc Access. 2005;6(1):29-33. doi:10.1177/112972980500600107Open DOISearch in Google Scholar
Ghorbani A, Aalamshah M, Shahbazian H, Ehsanpour A, Aref A. Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients. Indian J Nephrol. 2009;19(2):57-61. doi:10.4103/0971-4065.53323Open DOISearch in Google Scholar
Dember LM, Beck GJ, Allon M, et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA. 2008;299(18):2164-2171. doi:10.1001/jama.299.18.2164Open DOISearch in Google Scholar
Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-1367. doi:10.1093/eurheartj/ehaa575Open DOISearch in Google Scholar
Roe MT, Armstrong PW, Fox KAA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367(14):1297-1309. doi:10.1056/NEJMoa1205512Open DOISearch in Google Scholar
Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015. doi:10.1056/NEJMoa0706482Open DOISearch in Google Scholar
Baber U, Chandrasekhar J, Sartori S, et al. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention A Report From the PROMETHEUS Study.; 2017.Search in Google Scholar
James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010;122(11):1056-1067. doi:10.1161/CIRCULATIONAHA.109.933796Open DOISearch in Google Scholar
Mavrakanas TA, Kamal O, Charytan DM. Prasugrel and Ticagrelor in Patients with Drug-Eluting Stents and Kidney Failure. Clin J Am Soc Nephrol. 2021;16(5):757-764. doi:10.2215/CJN.12120720Open DOISearch in Google Scholar
Laine M, Lemesle G, Burtey S, et al. TicagRelor Or Clopidogrel in severe or terminal chronic kidney patients Undergoing PERcutaneous coronary intervention for acute coronary syndrome: The TROUPER trial. Am Heart J. 2020;225:19-26. doi:10.1016/j.ahj.2020.04.013Open DOISearch in Google Scholar